Physician profile
Mark Vexelman
NPI 1700896750
$3,262.81
in general payments reported to CMS, 2019-2025
35 companies · $50.90 in 2025
The $50.90 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,934 · 2020: $310 · 2021: $322 · 2022: $202 · 2023: $252 · 2024: $193 · 2025: $50.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $309.19 | 2019-2024 | |
| Novo Nordisk INC | $265.97 | 2019-2023 | Rybelsus, Ozempic |
| Smith+Nephew, INC. | $262.20 | 2019-2023 | Collagenase Santyl |
| Janssen Pharmaceuticals, INC | $241.26 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $240.66 | 2019-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $212.66 | 2019-2021 | |
| Glaxosmithkline, LLC. | $203.38 | 2019-2023 | Arexvy, Shingrix |
| Amarin Pharma, INC. | $202.38 | 2019-2020 | |
| Allergan, INC. | $161.93 | 2019-2020 | |
| Lilly USA, LLC | $149.55 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $145.30 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.41 | 2019-2023 | Jardiance |
| Ets Wound Care LLC | $95.37 | 2024 | Mirragen Advanced Wound Matrix |
| Amgen INC. | $79.38 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.59 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $61.62 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.92 | 2019-2023 | Xifaxan, Trulance |
| Tactile Systems Technology INC | $42.74 | 2019 | |
| Reapplix INC. | $33.79 | 2024 | 3c Patch Kit - Box |
| Mimedx Group, INC. | $31.43 | 2025 | |
| Sanofi-Aventis U.S. LLC | $28.69 | 2019 | |
| Kerecis Limited | $27.45 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $27.03 | 2023 | Rexulti |
| Solventum Corporation | $26.67 | 2024 | Activ.A.C. |
| Pacira Therapeutics, INC. | $22.67 | 2019 | |
| Astellas Pharma US INC | $22.67 | 2019 | |
| Lundbeck LLC | $22.51 | 2023 | Rexulti |
| Organogenesis INC. | $21.75 | 2021 | |
| Abbvie INC. | $20.74 | 2019 | |
| Hartmann USA, INC. | $19.47 | 2025 | Zetuvit Plus 10x10 P10 |
| Ironwood Pharmaceuticals, INC | $18.57 | 2019 | |
| Scilex Pharmaceuticals INC. | $17.75 | 2019 | |
| Medline Industries LP | $17.01 | 2022 | |
| Aroa Biosurgery Incorporated | $12.27 | 2020 | |
| Next Science LLC | $6.83 | 2023 | Surgx, Blastx, Xperience |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Vexelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.